Analysis of Infections and Humoral Immunity in Patients With RRMM Treated With Talquetamab Monotherapy in MonumenTAL-1


Dr Fonseca shares findings from the MonumenTAL-1 trial presented at ASCO 2023, suggesting potentially reduced infection rates in patients with relapsed/refractory multiple myeloma receiving talquetamab relative to BCMA-targeted agents.

Related Videos
Related Content